Initiating oral fingolimod treatment in patients with multiple sclerosis
Fingolimod, the first oral disease-modifying therapy (DMT) approved for the treatment of multiple sclerosis (MS) and the only sphingosine 1-phosphate receptor modulator approved for any disease state, represents an important addition to the expanding DMT options for patients with MS. In three large...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publishing
2013-07-01
|
| Schriftenreihe: | Therapeutic Advances in Neurological Disorders |
| Online-Zugang: | https://doi.org/10.1177/1756285613491520 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|